Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987816 | 0.98 | POLB (0.59) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL11987826 | 0.98 | POLB (0.59) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL10158642 | 0.96 | POLB (0.51) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL16519854 | 0.84 | POLB (0.53) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL11237572 | 0.79 | POLB (0.61) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL16423060 | 0.79 | POLB (0.56) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL16673447 | 0.79 | POLB (0.51) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL21027500 | 0.79 | POLB (0.51) | POLBADRA1DALDH1A1PKMMEN1 | |
| SCHEMBL22895103 | 0.77 | POLB (0.37) | POLBADRA1DALDH1A1MEN1GAA | |
| SCHEMBL3551196 | 0.75 | POLB (0.56) | POLBADRA1DALDH1A1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11586060-B2 | Optical filter with light source | SOLUTIA CANADA INC. (CA) | 2023-02-21 | — | — | US | disclosed |
| US-9910301-B2 | Switchable optical filter apparatus with light | SWITCH MATERIALS, INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| EP-2580207-B1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| US-9290440-B2 | Bicyclic compound | TOA EIYO LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150119418-A1 | BICYCLIC COMPOUND | TOA EIYO LTD. (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2013123592-A1 | OPTICAL FILTER WITH LIGHT SOURCE | SWITCH MATERIALS INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| US-8247550-B2 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120209005-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110282064-A1 | METHOD FOR THE MANUFACTURE OF HIGHLY PURE PRASUGREL | ZENTIVA K.S. (CZ) | 2011-11-17 | — | — | US | disclosed |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2009119088-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | POLB 2133/4885ADRA1D 2610/4885ALDH1A1 3488/4885 |
| US-20120209005-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, TEK, THPO | POLB 4165/4885ADRA1D 739/4885ALDH1A1 2398/4885 |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | POLB 2798/4885ADRA1D 3284/4885ALDH1A1 3393/4885 |
| US-20110282064-A1 | METHOD FOR THE MANUFACTURE OF HIGHLY PURE PRASUGREL | P2RY6, GP6, CYP2B6 | POLB 4066/4885ADRA1D 1622/4885ALDH1A1 687/4885 |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | POLB 1877/4885ADRA1D 4134/4885ALDH1A1 4256/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | POLB 2798/4885ADRA1D 3284/4885ALDH1A1 3393/4885 |
| US-20150119418-A1 | BICYCLIC COMPOUND | C1S, C1R, CYP11B2 | POLB 2833/4885ADRA1D 680/4885ALDH1A1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.